IL-17 Inhibition in Axial Spondyloarthritis
Danve A, Deodhar A. IL-17 Inhibition in Axial Spondyloarthritis. Current Treatment Options In Rheumatology 2015, 1: 221-230. DOI: 10.1007/s40674-015-0020-9.Peer-Reviewed Original ResearchIL-23/ILIL-17IL-23Monoclonal antibodiesExtra-articular manifestationsTNF-α blockadeIL-17 inhibitionIL-23 receptorQuality of lifeSignificant beneficial effectDisease activityProspective trialRadiographic progressionInhibitor medicationIL-12MRI scoresPhysical functionAxial spondyloarthritisClinical studiesP40 subunitAnimal modelsBeneficial effectsWestern populationsNovel optionSpondyloarthritis